Abstract:Background The novel coronavirus disease (COVID-19) has been declared a global pandemic, with the cumulative number of confirmed cases and deaths exceeding 150 million and 3 million, respectively. Here, we examined the dynamic changes in the immune and clinical features of patients with COVID-19. Methods Clinical data of 98 patients with confirmed COVID-19 diagnosis were acquired from electronic medical records and curated. The data were analyzed based on the stage of the admission, deterioration, and convalescence, which included age, sex, severity, disease stages, biochemical indicators, immune cells, inflammatory cytokines, and immunoglobulins. Additionally, temporal changes in the immune response in patients undergoing continuous renal replacement therapy (CRRT) were also examined. Results Compared to mild stage patients, severe stage patients with COVID-19 exhibited a significant reduction in lymphocyte [23.10 (17.58–33.55) vs. 4.80 (2.95–6.50), P<0.001], monocyte [8.65 (7.28–10.00) vs. 3.45 (2.53–4.58), P<0.001], and NK cell levels [244.00 (150.50–335.00) vs. 59.00 (40.00–101.00), P<0.001] but showed elevated levels of neutrophils [64.90 (56.30–73.70) vs. 90.95 (87.60–93.68), P<0.001], inflammatory cytokines [Interleukin-10, 3.05 (1.37–3.86) vs. 5.94 (3.84–8.35), P=0.001; and tumor necrosis factor-α, 11.50 (6.55–26.45) vs. 12.96 (12.22–36.80), P=0.029], which improved during convalescence. Besides, the number of immune cells—T lymphocytes, B lymphocytes, helper T cells, suppressor T cells, NK cells, and monocytes, except neutrophils—slowly increased in critically ill patients receiving CRRT from 0 to 3 weeks. Conclusions Our results indicate that the surveillance of immune cells may contribute to monitoring COVID-19 disease progression, and CRRT is a potential therapeutic strategy to regulate the immune balance in critically ill patients.

Comparative Analysis of Antimicrobial Antibodies between Mild and Severe COVID-19

Proteomics Investigation of Diverse Serological Patterns in COVID-19

COVID-19 neutralizing antibodies predict disease severity and survival

Analysis of related factors of plasma antibody levels in patients with severe and critical COVID-19

Analysis of the Dynamic Relationship Between Immune Profiles and the Clinical Features of Patients with COVID-19

COVID-19-neutralizing antibodies predict disease severity and survival

Deep dissection of the antiviral immune profile of patients with COVID-19

Impaired mucosal IgA response in patients with severe COVID-19

Dynamic Antibody Responses in Patients with Different Severity of COVID-19: A Retrospective Study

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

Disease-duration based comparison of subsets of immune cells in SARS CoV-2 infected patients presenting with mild or severe symptoms identifies prognostic markers for severity

The dynamic antibody responses on COVID-19 patients with different severity: A retrospective research

Clinical and immunological comparison of COVID-19 disease between critical and non-critical courses: a systematic review and meta-analysis

The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients

Unique immunological profile in patients with COVID-19

Titers of IgG and IgA against SARS-CoV-2 proteins and their association with symptoms in mild COVID-19 infection

Longitudinal Serum Proteome Characterization of COVID-19 Patients With Different Severities Revealed Potential Therapeutic Strategies

Parallel Dysregulated Immune Response in Severe Forms of COVID-19 and Bacterial Sepsis via Single-Cell Transcriptome Sequencing

The dynamics of immune response in COVID‐19 patients with different illness severity

Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities

Prevalence of anti-lymphocyte IgM autoantibodies driving complement activation in COVID-19 patients